title: Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review.
abstract: Efficacy of cisplatin versus cetuximab with radiation in locally advanced head and neck cancer (LAHNC) was evaluated. A total of 96 patients with newly diagnosed LAHNC treated at our institution between 2006 and 2011 with concurrent radiation and cisplatin (group A, n = 45), cetuximab (group B, n = 24), or started with cisplatin but switched to cetuximab because of toxicity (group C, n = 27) were reviewed. Chi-square test, analysis of variance, and log-rank test were used for analysis. The three groups had similar baseline characteristics, except for median age, T stage, albumin levels, hemoglobin levels, performance status, and comorbidities. A complete response (CR) was seen in 77%, 17%, and 67% of patients (P < 0.001), respectively. There was no significant difference in median overall survival (OS) between groups A and C. The median OS for groups A and C was not reached (>65 months), even though it was significantly longer than median OS for group B (11.6 months; P ≤ 0.001). The 2-year OS in groups A and C is significantly higher than that in group B (70% for groups A and C, 22% for group B). There is no significant difference in progression-free survival (PFS) between groups A and C. The median PFS for these groups was not reached (>62 months), and is significantly longer than that for group B (4.3 months; P ≤ 0.001). The 2-year PFS of group A (67%) and group C (76%) was significantly longer than that of group B (20%). Cisplatin with radiation appears to be more efficacious even in suboptimal dosing than cetuximab with radiation in LAHNC but the two groups were not well matched.
authors: Department of Medicine, Division of Hematology/Oncology, Louisiana State University Health, Shreveport, LA, USA. ; Feist-Weiller Cancer Center, Shreveport, LA, USA.
authors: Prakash
authors: P
authors: Peddi
authors: Department of Medicine, Division of Hematology/Oncology, Louisiana State University Health, Shreveport, LA, USA. ; Feist-Weiller Cancer Center, Shreveport, LA, USA.
authors: Runhua
authors: R
authors: Shi
authors: Department of Medicine, Division of Hematology/Oncology, Louisiana State University Health, Shreveport, LA, USA. ; Feist-Weiller Cancer Center, Shreveport, LA, USA.
authors: Binu
authors: B
authors: Nair
authors: Department of Medicine, Division of Hematology/Oncology, Louisiana State University Health, Shreveport, LA, USA. ; Feist-Weiller Cancer Center, Shreveport, LA, USA.
authors: Fred
authors: F
authors: Ampil
authors: Department of Medicine, Division of Hematology/Oncology, Louisiana State University Health, Shreveport, LA, USA. ; Feist-Weiller Cancer Center, Shreveport, LA, USA.
authors: Glenn M
authors: GM
authors: Mills
authors: Department of Internal Medicine, Division of Oncology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
authors: Syed H
authors: SH
authors: Jafri
keywords: cetuximab; cisplatin; head and neck cancer; overall survival; radiation therapy
references: Lancet Oncol. 2013 Mar;14(3):257-64
references: 23414589
references: Ann Oncol. 2002 Jul;13(7):995-1006
references: 12176777
references: Clin Transl Oncol. 2014 Apr;16(4):418-24
references: 24193865
references: J Clin Oncol. 2014 Sep 1;32(25):2735-43
references: 25049329
references: Head Neck. 2015 Mar;37(3):386-92
references: 24431011
references: Radiother Oncol. 2009 Jul;92(1):4-14
references: 19446902
references: Ann Oncol. 2011 Mar;22(3):712-7
references: 20810547
references: Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):676-81
references: 18355979
references: Oral Oncol. 2014 Nov;50(11):1041-8
references: 25176576
references: Radiother Oncol. 2011 Jul;100(1):33-40
references: 21684027
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: J Clin Oncol. 2003 Jan 1;21(1):92-8
references: 12506176
references: Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):915-22
references: 20947269
references: J Clin Oncol. 2014 Sep 20;32(27):2940-50
references: 25154822
references: N Engl J Med. 2003 Nov 27;349(22):2091-8
references: 14645636
references: N Engl J Med. 2008 Sep 11;359(11):1116-27
references: 18784101
references: N Engl J Med. 2006 Feb 9;354(6):567-78
references: 16467544
references: Oral Oncol. 2012 Mar;48(3):266-71
references: 22079100